IDEAYA Biosciences logo

IDEAYA Biosciences

IDYA | NASDAQ
Chart Builder DCF Calculator
$30.36
-$1.47 (-4.62%)
At close: Nov 16, 2026, 4:00 PM ET
$30.36
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.62%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
38.4
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #570/1021 (Top 56%)

Key Statistics

Market Data

Market Cap $3.13B
1D Range
30.27 32.46
52W Range
27.60 42.48

Valuation (TTM)

PE -6.76
PB 2.86
EV/EBITDA -4.08

Valuation (NTM)

Forward PE N/A
Forward PEG -0.03
Price Target $52.50
Loading financial charts...

Profile

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims ...

Sector Healthcare
Industry Biotechnology
Employees 145
IPO Date May 23, 2019
Fiscal Year January - December

Latest News

IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript

15 hours ago · seekingalpha.com

IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

1 day ago · gurufocus.com

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

13 days ago · prnewswire.com

IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates

14 days ago · zacks.com

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

14 days ago · prnewswire.com

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

21 days ago · zacks.com

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

2 months ago · prnewswire.com

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

2 months ago · seekingalpha.com

IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences

3 months ago · prnewswire.com

IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago · gurufocus.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$1.22
Miss -3.39%
REV
$10.24M
Beat +35.06%
Next Earnings
Feb 16, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$52.50
Upside
+72.92%
Buy (8)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.